FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2810973189> ?p ?o ?g. }

• W2810973189 abstract "Introduction Liquid biopsy research contributes to precision medicine initiatives and enables minimally invasive and inexpensive sampling compared to traditional tissue biopsy. However, the low amount of circulating tumour nucleic acid fragments in the blood presents significant challenges for accurate variant detection using NGS technology. Utilisation of both cell free (cf) DNA and cf RNA requires methods capable of interrogating both types of analytes to maximise the utility of each blood sample. We described here a two days sample-to-report workflow using Oncomine Pan-Cancer Cell-Free Assay that surveys oncology variants across multiple tumour types and simultaneously detects single nucleotide variants (SNVs) and structural variants such as copy number variations (CNVs), gene fusions as well as exon skipping. Material and methods Cell Free Total Nucleic Acid (cfTNA) was extracted using MagMAX Cell-Free TNA Isolation Kit. Internal 0.1% or 0.5% cfDNA reference materials were used to evaluate SNV sensitivity and specificity. For CNV sensitivity and specificity evaluation, cfDNA from CNV positive cell lines were titrated into normal donor plasma cfTNA background. All controls were verified with orthogonal assays of dPCR. Libraries were manually prepared and sequenced with Ion Chef and S5 XL System. Data analysis was performed in Torrent SuiteTM 5.6 and Ion Reporter 5.6. Results and discussions The Pan-Cancer Cell Free Research Assay utilised a single-pool multiplex assay to query more than 900 tumour driver and resistance hotspots. The broad content panel encompasses SNVs, CNVs, fusions, exon skipping as well as expanded coverage of TP53 exon regions for TP53 mutation analysis. The entire work flow (sample-to-report) could be as less as 30 hours and is compatible with Oncomine knowledgebase that allows customers easy access to the variant reports. The limit of detection (LOD) of 0.5% and 0.1% allelic frequency can be achieved with sensitivity of >99% and 90% respectively, both specificity >99.9%. Detection as low as 1.3 fold gene amplification can be obtained for 12 CNV targets with sensitivity of >96% and specificity of >99%. For fusion detection, as low as 1% RNA fusions in cfTNA can be achieved. Conclusion The Pan-Cancer Cell Free Research Assay provides an easy and quick NGS workflow that simultaneously analyses SNVs, CNVs, gene fusions and exon skipping across 52 genes associated multiple cancers. The 0.1% LOD enables accurate detection of low-abundance tumour variants for liquid biopsy research." @default.
• W2810973189 created "2018-07-10" @default.
• W2810973189 creator A5000713072 @default.
• W2810973189 creator A5013963805 @default.
• W2810973189 creator A5023151126 @default.
• W2810973189 creator A5039630179 @default.
• W2810973189 creator A5050358104 @default.
• W2810973189 creator A5068482916 @default.
• W2810973189 creator A5070370956 @default.
• W2810973189 creator A5071711572 @default.
• W2810973189 creator A5073809911 @default.
• W2810973189 date "2018-06-01" @default.
• W2810973189 modified "2023-09-23" @default.
• W2810973189 title "PO-086 An efficient ion torrent™ next generation sequencing workflow for liquid biopsy research to assess cell-free total nucleic acid" @default.
• W2810973189 doi "https://doi.org/10.1136/esmoopen-2018-eacr25.614" @default.
• W2810973189 hasPublicationYear "2018" @default.
• W2810973189 type Work @default.
• W2810973189 sameAs 2810973189 @default.
• W2810973189 citedByCount "0" @default.
• W2810973189 crossrefType "journal-article" @default.
• W2810973189 hasAuthorship W2810973189A5000713072 @default.
• W2810973189 hasAuthorship W2810973189A5013963805 @default.
• W2810973189 hasAuthorship W2810973189A5023151126 @default.
• W2810973189 hasAuthorship W2810973189A5039630179 @default.
• W2810973189 hasAuthorship W2810973189A5050358104 @default.
• W2810973189 hasAuthorship W2810973189A5068482916 @default.
• W2810973189 hasAuthorship W2810973189A5070370956 @default.
• W2810973189 hasAuthorship W2810973189A5071711572 @default.
• W2810973189 hasAuthorship W2810973189A5073809911 @default.
• W2810973189 hasBestOaLocation W28109731891 @default.
• W2810973189 hasConcept C10390740 @default.
• W2810973189 hasConcept C104317684 @default.
• W2810973189 hasConcept C121608353 @default.
• W2810973189 hasConcept C142724271 @default.
• W2810973189 hasConcept C152110520 @default.
• W2810973189 hasConcept C153911025 @default.
• W2810973189 hasConcept C164928082 @default.
• W2810973189 hasConcept C172680121 @default.
• W2810973189 hasConcept C185592680 @default.
• W2810973189 hasConcept C24107716 @default.
• W2810973189 hasConcept C2775934546 @default.
• W2810973189 hasConcept C2778258057 @default.
• W2810973189 hasConcept C2779234561 @default.
• W2810973189 hasConcept C2779529041 @default.
• W2810973189 hasConcept C2781188995 @default.
• W2810973189 hasConcept C43617362 @default.
• W2810973189 hasConcept C48126324 @default.
• W2810973189 hasConcept C49105822 @default.
• W2810973189 hasConcept C51679486 @default.
• W2810973189 hasConcept C54355233 @default.
• W2810973189 hasConcept C552990157 @default.
• W2810973189 hasConcept C60644358 @default.
• W2810973189 hasConcept C70721500 @default.
• W2810973189 hasConcept C71924100 @default.
• W2810973189 hasConcept C86803240 @default.
• W2810973189 hasConceptScore W2810973189C10390740 @default.
• W2810973189 hasConceptScore W2810973189C104317684 @default.
• W2810973189 hasConceptScore W2810973189C121608353 @default.
• W2810973189 hasConceptScore W2810973189C142724271 @default.
• W2810973189 hasConceptScore W2810973189C152110520 @default.
• W2810973189 hasConceptScore W2810973189C153911025 @default.
• W2810973189 hasConceptScore W2810973189C164928082 @default.
• W2810973189 hasConceptScore W2810973189C172680121 @default.
• W2810973189 hasConceptScore W2810973189C185592680 @default.
• W2810973189 hasConceptScore W2810973189C24107716 @default.
• W2810973189 hasConceptScore W2810973189C2775934546 @default.
• W2810973189 hasConceptScore W2810973189C2778258057 @default.
• W2810973189 hasConceptScore W2810973189C2779234561 @default.
• W2810973189 hasConceptScore W2810973189C2779529041 @default.
• W2810973189 hasConceptScore W2810973189C2781188995 @default.
• W2810973189 hasConceptScore W2810973189C43617362 @default.
• W2810973189 hasConceptScore W2810973189C48126324 @default.
• W2810973189 hasConceptScore W2810973189C49105822 @default.
• W2810973189 hasConceptScore W2810973189C51679486 @default.
• W2810973189 hasConceptScore W2810973189C54355233 @default.
• W2810973189 hasConceptScore W2810973189C552990157 @default.
• W2810973189 hasConceptScore W2810973189C60644358 @default.
• W2810973189 hasConceptScore W2810973189C70721500 @default.
• W2810973189 hasConceptScore W2810973189C71924100 @default.
• W2810973189 hasConceptScore W2810973189C86803240 @default.
• W2810973189 hasLocation W28109731891 @default.
• W2810973189 hasOpenAccess W2810973189 @default.
• W2810973189 hasPrimaryLocation W28109731891 @default.
• W2810973189 hasRelatedWork W2175630747 @default.
• W2810973189 hasRelatedWork W2186301014 @default.
• W2810973189 hasRelatedWork W2293182100 @default.
• W2810973189 hasRelatedWork W2323665326 @default.
• W2810973189 hasRelatedWork W2475991585 @default.
• W2810973189 hasRelatedWork W2482299481 @default.
• W2810973189 hasRelatedWork W2562369161 @default.
• W2810973189 hasRelatedWork W2612913435 @default.
• W2810973189 hasRelatedWork W2740048060 @default.
• W2810973189 hasRelatedWork W2740502707 @default.
• W2810973189 hasRelatedWork W2797111853 @default.
• W2810973189 hasRelatedWork W2885251340 @default.
• W2810973189 hasRelatedWork W2898510528 @default.
• W2810973189 hasRelatedWork W2954677762 @default.
• W2810973189 hasRelatedWork W3020141650 @default.
• W2810973189 hasRelatedWork W3033878702 @default.
• W2810973189 hasRelatedWork W3082219097 @default.

• next